Two numbers tell this story, and almost every account of it carries only the first.
India has reduced new tuberculosis cases by 21% between 2015 and 2024, against a global decline of about 12%. That is one of the fastest declines among high-burden countries, and it is real.
India's own target, under the National TB Elimination Programme, was an 80% reduction in incidence and a 90% reduction in mortality against 2015 levels, by 2025. That deadline has passed.
Both facts belong in the same paragraph. A programme can outperform the world and still fall well short of what it set out to do, and understanding why is far more useful than celebrating the first number or deriding the second.
What was announced
The Ministry of Health and Family Welfare issued a backgrounder, Towards a TB-Free India, on 13 October 2026, alongside the launch of a nationwide campaign.
JOSH — Joint Squad for Health — Teams were organised on 13 October 2026 across 11 states and 55 districts on a pilot basis. Each JOSH team combines MY Bharat volunteers, National Cadet Corps cadets, and a designated Class-I officer, tasked with spreading awareness on timely screening, treatment and adherence, and with addressing stigma.
The design is worth noticing. TB's hardest remaining problem is not drugs or diagnostics; it is the asymptomatic and the undiagnosed, and finding them requires somebody to knock on doors in neighbourhoods where a TB diagnosis is still socially costly. Putting NCC cadets and youth volunteers under an officer's supervision is an attempt to use the one mobilisable workforce the state has in every district. The Ministry had previously held workshops with Members of Parliament and State legislators, and the release is candid that institutional engagement alone was judged insufficient — community involvement was "deemed crucial".
The progress, with the arithmetic shown
The headline figures, drawn from the WHO's Global Tuberculosis Report 2025:
- Incidence fell from about 237 to 187 cases per lakh between 2015 and 2024 — a 21% reduction.
- Deaths fell from about 28 to 21 per lakh, a reduction of roughly 28%.
- Treatment coverage rose from 53% in 2015 to 92% in 2024, against global coverage of about 78%.
Programme outputs reported under TB Mukt Bharat Abhiyaan are substantial:
- Cumulative screenings have crossed 28.1 crore.
- Over 20 lakh people have been given TB Preventive Treatment (TPT).
- 5.7 lakh new Nikshay Mitras have been added.
- 46,118 Gram Panchayats have received TB-free certification.
- X-ray screening has increased 34-fold through handheld units.
- A TB Mukt Bharat App has been rolled out with an AI chatbot, 'Khushi', alongside AI-driven triage tools.
Of that list, the treatment coverage figure is the most important and the least discussed. Rising from 53% to 92% means the system now finds and treats nine in ten of the people it estimates are falling ill, where a decade ago it found barely half. Almost everything else follows from that, because an untreated case transmits.
The 34-fold increase in handheld X-ray screening is the operational reason it happened. A chest X-ray is the only practical way to find TB in someone who feels well, and until the machines became portable, screening meant persuading a healthy person to travel to a hospital. Moving the X-ray to the village inverts that, and AI triage then lets a handful of radiologists read a volume of films that would otherwise be unreadable.
Why the target was missed
Set the 21% against the 80% and the gap needs an explanation that is neither excuse nor indictment.
India chose a 2025 deadline when the global Sustainable Development Goal target is 2030. It set itself a harder deadline than the world's, and by a wide margin — an 80% cut in a decade is a steeper decline than any large country has achieved. Missing an ambitious self-imposed target is a different category of failure from missing a commonly agreed one, and it should be described as such.
But the scale of the shortfall points at something structural, and it is visible in the burden figures.
India accounts for about 25% of global TB cases — the largest share of any country, ahead of Indonesia at about 10% and the Philippines at under 7%. It accounted for roughly 28% of global TB deaths in 2024. And on drug resistance the concentration is worse still: India recorded about 32% of the world's multidrug-resistant and rifampicin-resistant cases.
A quarter of the world's caseload cannot be cleared by a programme operating at the pace of a normal health intervention, because TB is not only a medical problem. It is a disease of crowding, undernutrition and indoor air, and it tracks poverty precisely. Treatment cures the patient; it does not change the room they go home to. That is why nutritional support sits inside the programme at all — the Nikshay Poshan Yojana was raised from ₹500 to ₹1,000 per month from 1 November 2024, with benefits extended to family members, on the straightforward logic that an undernourished patient is both likelier to progress from infection to disease and likelier to abandon a long course of treatment.
BPaLM, and why it is the most consequential item
Buried in the technical list is the change that matters most to the hardest patients.
Drug-resistant TB was historically treated with regimens lasting 18 months or more, built on injectable drugs with severe side effects — hearing loss among them — and completed by only a minority of patients. BPaLM is a six-month, all-oral regimen of Bedaquiline, Pretomanid, Linezolid and Moxifloxacin. The World Health Organization recommends it in preference to the nine-month and longer regimens for multidrug-resistant and rifampicin-resistant TB, a recommendation it classes as conditional. India approved its introduction under the NTEP in September 2024.
The trial evidence is the part worth carrying. In the TB-PRACTECAL trial the six-month regimen produced treatment success of about 89% against 52% for the standard of care, with severe adverse events at 23% against 48%.
Read those two pairs together. The new regimen roughly doubles the chance of cure and roughly halves the chance of serious harm, while cutting treatment from eighteen months to six. In a condition where India's drug-resistant treatment success sits near 77% against about 90% for drug-sensitive disease, that is the single largest available improvement — and it is a reminder that shortening a regimen is itself a clinical intervention, because a course nobody finishes cures nobody and breeds further resistance.
What to watch
Three things, and none of them is a screening total.
Whether the 2025 target is formally reset. A missed deadline that is quietly dropped tells you less than one that is replaced with a dated, defensible successor. The SDG horizon of 2030 is the obvious candidate.
Whether drug-resistant case numbers fall. India's 32% share of global MDR and RR-TB is the figure that would most change the picture, and BPaLM is the instrument. Drug-resistant TB is largely created by interrupted treatment, so this number is a direct measure of how well the system holds on to patients.
Whether active case-finding reaches the people the clinic never sees. That is what JOSH is for, and the honest test of a campaign built on volunteers is not how many posts were shared but how many asymptomatic cases were found. Awareness is cheap to report and hard to verify; a notified case is neither.
The wider lesson generalises across Indian health policy, and it is the one this readership should take. Capacity at the point of delivery — the register, the screening device, the trained worker — is what converts a national commitment into a treated patient, which is why instruments like a scannable national register for allied health professions and 631 critical care blocks matter more than their announcements suggest. And as with the mental health treatment gap, the binding constraint has moved from awareness to the capacity waiting on the other side of detection.
🔑 Revision block
- What: PIB backgrounder Towards a TB-Free India, 13 October 2026, with the launch of JOSH (Joint Squad for Health) Teams across 11 states and 55 districts on a pilot basis.
- JOSH composition: MY Bharat volunteers + NCC cadets + a designated Class-I officer per team; focus on screening, early detection, adherence and stigma; a Jan Andolan approach.
- Progress (WHO Global TB Report 2025): incidence 237 → 187 per lakh (2015-2024), a 21% fall against about 12% globally; deaths 28 → 21 per lakh (about 28% down); treatment coverage 53% → 92% against global 78%.
- The target missed: NTEP aimed at 80% lower incidence and 90% lower mortality against 2015, by 2025 — against an SDG horizon of 2030. The deadline has passed.
- Burden: India has about 25% of global TB cases (largest of any country, ahead of Indonesia ~10%), about 28% of global TB deaths, and about 32% of global MDR/RR-TB cases.
- Programme outputs: 28.1 crore cumulative screenings; over 20 lakh given TB Preventive Treatment (TPT); 5.7 lakh new Nikshay Mitras; 46,118 Gram Panchayats TB-free certified; 34-fold rise in handheld X-ray screening; TB Mukt Bharat App with the AI chatbot 'Khushi'.
- Nutrition: Nikshay Poshan Yojana raised from ₹500 to ₹1,000 per month from 1 November 2024, extended to family members.
- BPaLM: six-month, all-oral regimen — Bedaquiline, Pretomanid, Linezolid, Moxifloxacin — WHO-recommended over 9-month and 18-month regimens for MDR/RR-TB; adopted under NTEP in September 2024. TB-PRACTECAL: success 89% vs 52%, severe adverse events 23% vs 48%.
- Treatment success: about 77% for MDR/RR-TB against about 90% for drug-sensitive TB.
- The pathogen: TB is caused by Mycobacterium tuberculosis.
- Exam hook: TB tracks crowding, undernutrition and indoor air. Treatment cures the patient but does not change the room they return to — which is why nutritional support sits inside a disease-control programme.
🎯 Practice MCQs
Q1. Between 2015 and 2024, India's TB incidence fell by approximately: (a) 12% (b) 21% (c) 45% (d) 80%
→ (b) Against a global decline of about 12%. The 80% figure was India's own national target for 2025, which was not met.
Q2. India's share of global TB cases is approximately: (a) 25%, the largest of any country (b) 10%, second after Indonesia (c) 6%, comparable to China (d) 40%, more than all other countries combined
→ (a) Indonesia follows at about 10% and the Philippines at under 7%.
Q3. The BPaLM regimen consists of: (a) Isoniazid, Rifampicin, Ethambutol and Pyrazinamide (b) Bedaquiline, Pretomanid, Linezolid and Moxifloxacin (c) Streptomycin, Kanamycin, Amikacin and Capreomycin (d) Rifapentine, Isoniazid, Bedaquiline and Delamanid
→ (b) A six-month, all-oral regimen for drug-resistant TB, recommended by WHO over the 9-month and 18-month alternatives.
Q4. India's treatment coverage for TB in 2024 stood at about: (a) 53% (b) 64% (c) 78% (d) 92%
→ (d) Up from 53% in 2015, against global coverage of about 78%. The 53% figure is India's 2015 baseline.
Q5. JOSH Teams, launched in October 2026, comprise: (a) MY Bharat volunteers, NCC cadets and a designated Class-I officer (b) ASHA workers and Anganwadi supervisors only (c) District Collectors and Chief Medical Officers (d) Private practitioners empanelled under Ayushman Bharat
→ (a) Piloted across 11 states and 55 districts, aimed at awareness, early detection, adherence and reducing stigma.
Q6. Under the Nikshay Poshan Yojana, monthly nutritional support was raised from: (a) ₹250 to ₹500 (b) ₹1,000 to ₹2,000 (c) ₹500 to ₹1,000 (d) ₹1,500 to ₹3,000
→ (c) Effective 1 November 2024, with benefits extended to family members.
Q7. In the TB-PRACTECAL trial, treatment success with the six-month regimen compared with the standard of care was: (a) 52% versus 89% (b) 77% versus 90% (c) 89% versus 52% (d) 23% versus 48%
→ (c) The 23% versus 48% pair refers to severe adverse events, which the shorter regimen roughly halved.
Q8. India's share of global multidrug-resistant and rifampicin-resistant TB cases is approximately: (a) 8% (b) 15% (c) 21% (d) 32%
→ (d) The highest in the world, and the figure that would most change India's overall TB picture if reduced.
Q9. Tuberculosis is caused by: (a) Mycobacterium tuberculosis (b) A retrovirus transmitted through blood (c) Mycobacterium leprae (d) A protozoan parasite spread by mosquitoes
→ (a) Mycobacterium leprae causes leprosy. TB spreads through airborne droplets, which is why crowding and indoor air matter so much.
Q10. Why does a disease-control programme include nutritional support? (a) Because the drugs cannot be absorbed without supplements (b) Because nutrition replaces the need for chemotherapy (c) Because undernourished patients are likelier to progress to disease and to abandon long treatment (d) Because WHO makes it a condition of drug supply
→ (c) TB tracks undernutrition and crowding, so treatment alone does not alter the conditions a patient returns to.
📋 How this gets asked (PYQ pattern)
TB is among the most reliably examined public-health topics, and it rewards a small number of precise facts.
The first is the pathogen and the programme name. Mycobacterium tuberculosis; the National TB Elimination Programme, renamed from the Revised National TB Control Programme. Papers test the rename and the organism as separate one-mark items.
The second is the scheme set: Nikshay as the notification and tracking portal, Nikshay Poshan Yojana for nutritional support, Nikshay Mitra for community adoption of patients, and TB Mukt Bharat Abhiyaan as the umbrella campaign. The commonest error is to confuse Nikshay Mitra with Nikshay Poshan Yojana — one is a donor-volunteer, the other a cash transfer.
The third is the two deadlines, and this is where current-affairs reading pays. India's target year was 2025; the global SDG target is 2030. A question asserting that India's target matched the SDG timeline is wrong, and a candidate who knows India set the harder date understands the topic better than one who only knows a number.
The fourth is the regimen acronym. BPaLM expands to Bedaquiline, Pretomanid, Linezolid, Moxifloxacin. Acronym-expansion questions are free marks and this one is new enough to be attractive to examiners.
For a written answer, the argument that separates a good script is the one about the gap. State that India reduced incidence faster than the world and still missed its own target by a wide margin; that it carries a quarter of global cases and a third of drug-resistant cases; and that the remaining burden is concentrated in crowding and undernutrition rather than in missing drugs. Then say what would prove progress — falling drug-resistant numbers and asymptomatic cases found — rather than screening totals. That is an analysis. Reciting 28.1 crore screenings is not.
Preparing for CDS/OTA? On any health programme, separate the output from the outcome: screenings and app downloads are outputs, notified cases and treatment success are outcomes. Build the base with our CDS/OTA study material and the polity section, follow the daily CDS current affairs, and prepare with our faculty in the upcoming Cavalier courses in Delhi.
✍️ Written by The Cavalier Faculty Desk — Polity & Social Justice, at The Cavalier. Reviewed by the Cavalier Faculty Desk.